Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza

Clicks: 265
ID: 271531
2008
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
In the absence of a parenteral drug, oral oseltamivir is currently recommended by the WHO for treating H5N1 influenza. Whether oseltamivir absorption is adequate in severe influenza is unknown. We measured the steady state, plasma concentrations of nasogastrically administered oseltamivir 150 mg bid …
Reference Key
wr2008plososeltamivir Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Taylor WR;Thinh BN;Anh GT;Horby P;Wertheim H;Lindegardh N;de Jong MD;Stepniewska K;Hanh TT;Hien ND;Bien NM;Chau NQ;Fox A;Ngoc NM;Crusat M;Farrar JJ;White NJ;Ha NH;Lien TT;Trung NV;Day N;Binh NG;;
Journal PloS one
Year 2008
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/18923671
Keywords
respiration Gastrointestinal National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine pregnancy treatment outcome research support non-u.s. gov't adult female male aged Clinical Trial Artificial area under curve viral load influenza human / drug therapy* intubation antiviral agents / therapeutic use influenza a virus oseltamivir / administration & dosage h5n1 subtype* pmid:18923671 pmc2565445 doi:10.1371/journal.pone.0003410 walter r j taylor bui nghia thinh nguyen gia binh hemofiltration h3n2 subtype* oseltamivir / blood oseltamivir / metabolism oseltamivir / pharmacokinetics*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.